Immunic Stock Scheduled to Reverse Split on Monday, April 27th (NASDAQ:IMUX)

Key Points

• 1-for-10 reverse split will take effect on the morning of Monday, April 27, with shareholders' holdings adjusted after the market closes on Sunday, April 26.
• Shares traded down 5.9% to $1.11 (market cap ~$144.8M); Immunic last reported quarterly EPS of ($0.12) versus ($0.10) expected and analysts forecast roughly a -$0.94 EPS for the fiscal year.
• Analyst sentiment is mixed but tilted positive, with an average rating of "Moderate Buy" and a consensus price target of about $6.17.

Immunic, Inc. (NASDAQ:IMUX - Free Report) shares are going to reverse split on the morning of Monday, April 27th. The 1-10 reverse split was recently announced. The number of shares owned by shareholders will be adjusted after the market closes on Sunday, April 26th.

Immunic Trading Down 5.9%

Shares of NASDAQ:IMUX traded down $0.07 during trading on Wednesday, reaching $1.11. The stock had a trading volume of 3,530,615 shares, compared to its average volume of 3,321,654. The firm's 50-day simple moving average is $1.06 and its 200 day simple moving average is $0.83. Immunic has a one year low of $0.51 and a one year high of $1.51. The company has a market capitalization of $144.81 million, a P/E ratio of -1.59 and a beta of 1.37.

Immunic (NASDAQ:IMUX - Get Free Report) last posted its quarterly earnings data on Thursday, February 26th. The company reported ($0.12) EPS for the quarter, missing the consensus estimate of ($0.10) by ($0.02). Equities research analysts forecast that Immunic will post -0.94 earnings per share for the current fiscal year.

Analyst Ratings Changes

IMUX has been the topic of a number of research analyst reports. Guggenheim started coverage on Immunic in a research note on Tuesday, March 24th. They set a "buy" rating and a $7.00 price target on the stock. HC Wainwright lowered their price target on Immunic from $8.00 to $5.00 and set a "buy" rating for the company in a research report on Monday, March 2nd. Weiss Ratings restated a "sell (e+)" rating on shares of Immunic in a research note on Monday, December 29th. D. Boral Capital lowered shares of Immunic from a "buy" rating to a "hold" rating in a research report on Wednesday. Finally, Wall Street Zen raised shares of Immunic from a "sell" rating to a "hold" rating in a report on Saturday. Two analysts have rated the stock with a Strong Buy rating, five have assigned a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $6.17.

Institutional Investors Weigh In On Immunic

A number of institutional investors have recently modified their holdings of the business. Qube Research & Technologies Ltd purchased a new position in Immunic during the third quarter worth approximately $29,000. Two Sigma Investments LP acquired a new position in Immunic during the third quarter worth $52,000. HB Wealth Management LLC acquired a new stake in shares of Immunic in the third quarter valued at about $81,000. Seven Fleet Capital Management LP purchased a new stake in shares of Immunic during the fourth quarter worth about $83,000. Finally, Virtu Financial LLC purchased a new position in Immunic in the 3rd quarter valued at about $99,000. 51.82% of the stock is currently owned by institutional investors and hedge funds.

About Immunic

Immunic, Inc is a clinical-stage biopharmaceutical company focused on developing novel oral therapies to treat chronic inflammatory and autoimmune diseases as well as certain cancers. The company's research strategy centers on small-molecule immunology, aiming to offer targeted treatments with improved safety and tolerability profiles. By modulating key signaling pathways within the immune system, Immunic seeks to address underlying disease mechanisms and achieve durable therapeutic benefits for patients.

Immunic's lead product candidate, vidofludimus calcium (IMU-838), is an oral selective dihydroorotate dehydrogenase (DHODH) inhibitor in Phase 2 clinical development for conditions including ulcerative colitis, Crohn's disease and relapsing multiple sclerosis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.